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Background: Perioperative lidocaine infusion improves postoperative outcomes, mostly after abdominal and 
urologic surgeries. Knowledge of the effect of lidocaine on peripheral surgeries is limited. Presently, we investigated 
whether intraoperative lidocaine infusion reduced anesthetic consumption, duration of ileus, pain intensity, 
analgesic consumption and hospital stay after breast plastic surgeries. 
Methods: Sixty female patients, aged 20-60 years, enrolled in this prospective study were randomly and equally 
divided to two groups. One group (n = 30) received a 1.5 mg/kg bolus of lidocaine approximately 30 min before 
incision followed by continuous infusion of lidocaine (1.5 mg/kg/h) until skin closure (lidocaine group). The 
other group (n = 30) was untreated (control group). Balanced inhalation (sevoflurane) anesthesia and multimodal 
postoperative analgesia were standardized. End tidal sevoflurane concentration during surgery, time to the first flatus 
and defecation, visual analog pain scale (0-10), analgesic consumption and associated side effects at 24, 48, and 72 
h after surgery, hospital stay, and patient’s general satisfaction were assessed.
Results: Compared to the control group, intraoperative lidocaine infusion reduced by 5% the amount of sevoflurane 
required at similar bispectral index (P = 0.014). However, there were no significant effects of lidocaine regarding the 
return of bowel function, postoperative pain intensity, analgesic sparing and side effects at all time points, hospital 
stay, and level of patient’s satisfaction for pain control. 
Conclusions: Low dose intraoperative lidocaine infusion offered no beneficial effects on return of bowel function, 
opioid sparing, pain intensity and hospital stay after various breast plastic surgeries. (Korean J Anesthesiol 2012; 62: 
429-434)
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Introduction
Although ileus after surgery often occurs after intraperitoneal 
surgeries, delayed gastrointestinal motility has been demon-
strated after retroperitoneal and peripheral operations [1,2]. 
Postoperative ileus sometimes can be a potentially extensive 
and can be of considerable clinical significance, delaying 
hospital discharge [1,3-5]. A smooth and facilitated post  ope-
rative course, including adequate pain control and early oral 
intake, is often part of contributes to satisfaction in surgical 
patients. Although the use of opioids remains as the mainstay 
for postoperative pain control, consumption of opioid-based 
analgesics can be a potential factor in impairing colonic 
movement [6]. Thus, adjuvant analgesic therapies have been 
implemented to reduce the doses of opioids after surgery. 
In recent studies, perioperative systemic lidocaine infusion 
has demonstrated beneficial effects on the early restoration of 
bowel function, pain control, narcotic sparing and decreased 
hospital stay, particularly after abdominal and urologic surgeries 
[1,4,7-9]. Although delayed restoration of bowel activity 
following surgeries other than the abdominal area has been 
suggested [1,2], there have been few studies of the perioperative 
effect of lidocaine on bowel function after peripheral surgery. 
As a sodium channel blocker, systemic lidocaine attenuates 
skin pain in response to mechanical or chemical stimuli through 
peripheral and central mechanisms in preclinical human 
volunteer tests [10-12]. However, although the perioperative 
administration of lidocaine can prevent postoperative pain from 
various abdominal surgeries, the use of a low dose of lidocaine 
was not successful on the improvement of postoperative pain 
control and narcotic reduction in a recent study involving total 
hip arthroplasty [13].
The positive impact of systemic lidocaine on the post  ope-
rative outcomes has been mixed in previous studies. There  fore, 
we aimed to examine whether intraoperative systemic lidocaine 
may present beneficial effects on the recovery of bowel 
function, pain intensity and analgesic consumption in patients 
undergoing various breast plastic surgeries. 
Materials and Methods 
After obtaining our institutional ethics committee approval 
and written informed consent from each patient, ASA I-II 
patients (n = 60), between the ages of 20 and 60 years, under-
going elective plastic breast surgeries such as aesthetic augmen-
tation mammaplasty, reduction mammaplasty, augmen-
tation mammaplasty with tissue expander removal, breast 
reconstruction with flap including extended latissimus dorsi 
(ELD), deep inferior epigastric perforator (DIEP), and trans  -
verse rectus abdominis musculocutaneous (TRAM) following 
immediate or delayed mastectomy or tissue expander insertion 
following mastectomy with general anesthesia were randomly 
divided into two groups to receive systemic lidocaine infusion 
until the end of surgery (lidocaine group, n = 30) and no 
infusion (control group, n = 30) after induction of general 
anesthesia. For lidocaine group, an intravenous (i.v.) bolus of 
lidocaine 1.5 mg/kg was given approximately 30 min prior to 
the skin incision, followed by a continuous lidocaine infusion 
1.5 mg/kg/h throughout surgery until the end of skin closure. 
Patients enrolled in this study had no severe hepatic, renal, 
cardiac, respiratory, or endocrine diseases, morbid obesity, or 
allergies to local anesthetics. The episodes of intraoperative 
hypotension (mean blood pressure [BP] < 60 mmHg) or 
bradycardia (heart rate [HR] < 40 beats/min), arrhythmia or 
urticaria associated with lidocaine infusion were also criteria 
for exclusion. Surgical variation was limited because two 
plastic surgeons involved in this study were highly experienced 
in plastic breast surgeries, and had performed standardized 
operative techniques according to the surgery types. General 
anesthesia was induced with midazolam 2 mg and propofol 2 
mg/kg i.v. under mask ventilation with oxygen and sevoflurane, 
and rocuronium 0.8 mg/kg was followed for tracheal intubation. 
Anesthesia was maintained with sevoflurane with oxygen and 
medical air 1 L/1 L during anesthesia. No supplemental opioid 
was given to patients in either group during the maintenance of 
anesthesia. Patients were monitored throughout operation with 
BP, HR, peripheral oxygen saturation, EKG, core temperature, 
bispectral index (BIS), end tidal sevoflurane and end tidal 
CO2. Sevoflurane concentration was adjusted according to the 
hemodynamic and BIS values. BP and HR were maintained 
within 20% of preoperative values and BIS ranged 35-45 to 
ensure similar anesthetic depth between the groups. End 
tidal CO2 was between 35-40 mmHg. To maintain core body 
temperature normothermia, circulating warm water blanket 
and heated warm circuit were applied. Perioperative fluid was 
managed with Lactate Ringer’s solution at a rate 6-8 ml/kg/
h. At the end of surgery, neuromuscular blockade was reversed 
with pyridostigmine and glycopyrrolate (0.3 mg/kg and 0.015 
mg/kg, respectively). For postoperative pain control, pethidine 
0.5 mg/kg was provided within 30 min of the end of surgery and 
supplemented after recovery as needed with further boluses 
of 0.25 mg/kg at 20-30 min intervals. Upon arrival to the 
post anesthetic care unit (PACU), patients were connected to 
an intravenous patient controlled analgesic system (IVPCA) 
with fentanyl 1,500 μg and ketorolac 180 mg in 64 ml of saline 
(100 ml of total volume) to deliver a bolus of 1 ml of the above 
analgesics with a lockout time of 15 min and a basal rate of 1 
ml/h. During their PACU time, patients were asked to report 
any side effects of systemic lidocaine such as light-headedness, 
drowsiness, metal taste, perioral numbness, and visual 431 www.ekja.org
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disturbances. After transfer to the ward, all patients received 
IVPCA, and extra rescue medications such as pethidine or non-
steroid anti-inflammatory drug (NSAID) according to body 
weight, if required. 
Prior to the start of surgery, patients were instructed by a 
nurse anesthetist how to complete a written self assessment 
concerning the times to first flatus and first defecation, which 
indicated restoration of bowel function. The total amount 
of IVPCA, frequency and total dose of extra analgesics, and 
opioids associated side effects such as nausea, vomiting, 
itching, respiratory depression and urinary retention, and 
pain intensity on a visual analog scale (VAS) ranged 0-10 (0 = 
no pain, 10 = most intense pain ever) at 24, 48, and 72 h after 
surgery, and the level of satisfaction for pain control at 72 h 
after surgery were assessed by a medical investigator. For the 
safety of patients, anesthesiologists involved in the anesthetic 
managements were not blinded to the groups. However, they 
were not involved in further management of postoperative 
pain control or data collection associated with this study. 
Participating patients, surgeons, and medical investigators who 
were involved in the data collection, were all blinded to the 
patient’s group assignment. All patients successfully completed 
the study. No patient was dropped due to any anesthetic or 
surgical complication. 
The primary end point in the current study was restoration of 
bowel function after surgery. Power analysis was based on prior 
data [1], and our own pilot study. Twenty patients per group 
was necessary to permit a 12 h difference in the return of bowel 
function between the two groups, at α level of 0.05 with 80% 
power. Consideration to various type of surgeries in the current 
study, we enrolled patients until 60 patients (n = 30/group) 
completed the study. 
Statistical analysis for comparison between the two groups 
was conducted using SPSS, version 16 (SPSS Inc, Chicago, IL, 
USA). Comparison of parametric data and non-parametric data 
between the two groups was analyzed by using Student’s t-test 
or Mann Whitney rank sum test, depending on distributional 
properties. Chi-square test or Fisher’s exact test was used for the 
incidence of side effects. Data are expressed as mean ± standard 
deviation (SD), median (ranges) or number of patients. P < 0.05 
was considered statistically significant. 
Results
Vital signs of the patients remained stable at all times 
during the operation and PACU in either group. No patient in 
the lidocaine group showed lidocaine associated arrhythmia, 
severe bradycardia or hypotension during surgery, or delayed 
recovery from anesthesia. After transfer to the PACU, no 
patient of the lidocaine group reported subjective symptoms 
of lidocaine related adverse side effects. Demographic and 
clinical data, such as surgical types, mean BIS score during 
surgery, duration of surgery and opioid amount during PACU 
were comparable between the groups. However, intraoperative 
anesthetic requirement was significantly less with lidocaine 
administration. The mean sevoflurane end tidal concentration 
(from the skin incision to the skin closure) was 5% lower in the 
lidocaine group than the control group during the operation (Et 
sevoflurane, control group 1.95 ± 0.28% vs. lidocaine group 1.85 
± 0.26%, P = 0.014) at similar hemodynamic variables and BIS 
Table 1. Demographic Characteristics, Type of Surgery, and Perioperative Data 
  Variables  Control group (n = 30)  Lidocaine group (n = 30)  P
Age (yr)                             40 ± 8                     41 ± 10                0.784
Weight (kg)                          55 ± 7                     56 ± 5                 0.599
Height (cm)                         160 ± 5                    160 ± 1                 0.844
Type of surgery (n)
    Augmentation mammaplasty            5                         8
    Reduction mammaplasty               1                         1
    TER + Aug.mamaplasty
        Single/Both                      5/2                       3/4
    Breast reconstruction with flap
        ELD/DIEP/TRAM flap            5/5/1                     6/4/0
    Mastectomy with implant              6                         4
Et Sevoflurane (%)                  1.95 ± 0.28                 1.85 ± 0.26                0.014
Bispectral index                    39.2 ± 2.6                  38.9 ± 3.3                  0.977
Duration of surgery (min)          288 (210-520)                295 (240-500)               0.871
Opioid requirement during PACU
        No of patients                  20                       17
    Pethidine (mg)/patient          30.2 ± 13.3                  37.4 ± 13.1                 0.221
Data present mean ± SD, median (range) or number of patients. TER: tissue expander removal, ELD: extended latissimus dorsi, DIEP: deep 
inferior epigastric perforator, TRAM: transverse rectus abdominis musculocutaneous, Et: end tidal, PACU: postoperative care unit.432 www.ekja.org
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score (Table 1).
The times to the first flatus and defecation occurred appro-
ximately 5 h and 6 h faster in the lidocaine group than those of 
control group, respectively. However, these were not statistically 
significant differences. Recovery of bowel function after com-
pletion of surgery was not benefited by intraoperative small 
dose lidocaine infusion. When the duration of hospital stay was 
examined, there was no difference between the two groups 
(Table 2).
There was no significant difference regarding the effects of 
lidocaine on pain score, pain rescue analgesic consumption 
and analgesic associated adverse events at 24, 48 and 72 h after 
surgery, and level of satisfaction for pain control at 72 h after 
surgery, respectively (Table 3). Although severe postoperative 
pain has been noted in a few patients, presently the pain scores 
were consistent with “mild pain” (average VAS score < 4) for 
most of the patients in the both groups. Furthermore, a few 
patients of each group did not require IVPCA for pain control 
from postoperative day 2. Level of satisfaction for pain control 
during 72 h after surgery was presented as more than satisfied 
in the all patients of the both groups (Table 3). 
Discussion
In line with previous studies [5,8,9], the current results demon  -
strated that intraoperative systemic lidocaine administration 
of 1.5 mg/kg/h until the end of skin closure following a bolus 
lidocaine of 1.5 mg/kg as adjunctive anesthetic significantly 
reduced sevoflurane requirement by 5% in female patients during 
a variety of aesthetic and reconstructive breast surgeries at the 
similar BIS level of control patients. However, we observed no 
differences between the control group and the lidocaine group 
subjects regarding postoperative outcomes, such as restoration 
of bowel function, pain intensity, analgesic consumption, 
analgesic associated side effects, level of satisfaction for pain 
control, and the length of hospital stay. 
It is important to care for patients without postoperative 
morbi  dity to ensure patients satisfaction during the post-
operative course. The decreased gastrointestinal motility, 
Table 3. Analgesic Use and Side Effects, and VAS Score after Surgery
  Variables                          Control group (n = 30)      Lidocaine group (n = 30)        P
24 h after surgery, n                  30                      30
Total PCA (ml)                     23.8 ± 16.8               25.5 ± 14.7                  0.861
Extra pain rescue medication
    No. of patients                   1                        4
    Amount/patient                  K30                     2: K30 + D 50
      2: D 50
VAS score                          3.5 ± 1.7                  3.4 ± 1.6                  0.944
Side effect (N/V/D/I/RD) (n)           11/5/3/6/0                 14/8/1/8/0                  NS
48 h after surgery, n                  27                      28
Total PCA (ml)                     28.8 ± 15.6               23.8 ± 16.8                  0.683
Extra pain rescue medication
    No of patients                    1                       1
    Amount/patient                   K30                    K30
VAS score                         3.0 ± 1.9               2.4 ± 1.4                   0.321
Side effect (N/V/D/I/RD)             3/1/2/2/0                6/1/1/3/0                  NS
72 h after surgery, n                 22                      26
Total PCA (ml)                    28.5 ± 13.7              20.9 ±17.6                    0.221
Extra pain rescue medication
    No of patients                    1                      1
    Amount/patient                   K30                   K30
VAS score                          2.1 ± 1.6               1.9 ± 1.4                     0.87
Side effect (N/V/D/I/RD)             6/0/1/1/0               4/1/1/0/0                      NS
Level of satisfaction for pain control 
  (excellent/satisfied/poor)              0/28/0                 1/29/0                       NS
Data are mean ± SD or number of patients. PCA: patient controlled analgesia. PCA consists of fentanyl 1,500 mcg + ketorolac 180 mg + normal 
saline 62 ml per 100 ml. VAS: visual analog scale. N/V/D/I/RD: nausea/vomiting/itching/respiratory depression.K30: 30 mg of ketorolac as one 
dose, D50: demerol (pethidine chloride) 50 mg. NS: not significant. A few patients of each group did not require IVPCA for pain control from 
postoperative day 2.
Table 2. Recovery of Bowel Function and Duration of Hospital Stay
  Control group    Lidocaine group  
      P
  (n = 30)  (n = 30)
First flatus (h)   24.2 ± 13.7               19.4 ± 10.4              0.132
First defecation (h)         69.3 ± 40.9               63.2 ± 31.1              0.521
Hospital stay (d)           11.2 ± 4.7                11.0 ± 1.7                0.959
Data are mean ± SD.433 www.ekja.org
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associated with nausea, vomiting and delayed oral intake, 
which may decrease general satisfaction to surgical patients, 
often occurs after intra-peritoneal surgeries. However, episodes 
of ileus after extra-peritoneal surgeries were evident [1,2]. 
Although the underlying mechanisms of ileus after surgery were 
not clarified yet, opioid use [6] for adequate pain control and 
surge of inflammatory mediators [4,5] in response to surgical 
stress are thought to be causal factors. Recently, in an effort to 
minimize postoperative opioids consumption, multimodal co-
analgesics have been studied. Perioperative local anesthetic 
lidocaine infusion as an alternative approach significantly 
improved outcomes including the spared use of opioids and 
recovery of bowel function, particularly after abdominal and 
urologic surgeries [1,4,7-9]. Local anesthetic lidocaine reduces 
overactive inflammatory responses, which contribute to the 
development of several bowel diseases. Recently, Herroeder et 
al. [4] demonstrated that perioperative intravenous lidocaine 
significantly attenuated plasma levels of pro-inflammatory 
cytokines, complement and platelet-leukocyte aggregates after 
colorectal surgery. Furthermore, rapid return of bowel function 
by perioperative systemic lidocaine infusion was well associated 
with early hospital discharge after abdominal and urologic 
surgeries [1,3,4]. Interestingly, delay of bowel function following 
operations other than abdominal area has been described [2]. 
In that study, a delay of about 16 h before restoration of bowel 
activity following peripheral operations has been demonstrated 
radiologically using radiopaque markers. Although we are 
unsure as to the effect of perioperative systemic lidocaine 
infusion on the improvement of bowel function after peripheral 
surgeries, when considering a delayed gastrointestinal motility 
after peripheral surgeries, it might be worthwhile to study the 
effect of systemic lidocaine on the ileus after breast surgeries. 
Although radiopaque markers were not used, and the reason 
for the absence of an expected lidocaine effect on the recovery 
of bowel function was beyond the scope of this study, the time 
to the first experience of flatus and defecation after surgery were 
faster average 5 h and 6 h, respectively, in the lidocaine group 
subjects compared to control group patients. However, the 
differences were not statistically significant in this study. 
The mechanism of analgesic and antihyperalgesic effect by 
lidocaine have been explained by suppressing the excessive 
inputs from peripheral and spinal nerves after trauma in vivo 
human experiments [10-12]. The effect of systemic lidocaine 
on the attenuation of pain in response to experimental incision 
induced pain [11] or intradermal capsacin-induced secondary 
hyperalgesia [10,12] was demonstrated in the lidocaine treated 
group of preclinical human volunteer tests. In previous studies 
with retropubic prostatectomy [1], major abdominal surgery [7], 
laparoscopic colectomy [8], and laparoscopic cholecystectomy 
[9], perioperative lidocaine infusion reduced postoperative 
pain intensity and analgesic consumption. Particularly, the 
analgesic effect was significant on the third postoperative day 
after stopping lidocaine infusion in patients undergoing major 
abdominal surgery, by the preventive property of lidocaine on 
the induction of central hyperalgesia [7]. In contrast to results 
reported in abdominal and urologic surgeries with positive 
analgesic effects, i.v. bolus lidocaine of 1.5 mg/kg followed 
by continuous infusion of 3 mg/kg/h until the end of surgery 
failed to demonstrate any benefits for postoperative outcomes 
in patients after abdominal hysterectomy [14]. The true benefit 
of systemic lidocaine on the outcomes after abdominal and 
urologic surgery is uncertain, because systemic lidocaine has 
been continued over the postoperative periods 1-24 h after 
intraoperative infusion with different doses [1,4,7-9]. Reduced 
postoperative pain and the narcotic sparing effect by the i.v. 
infusion of lidocaine demonstrated in previous abdominal and 
urologic studies cannot be extrapolated to the current breast 
surgeries. 
Presently, pain intensity at rest was minor, with a VAS score 
of approximately 3, and consumption of PCA was similar 
between the control group and the lidocaine treated group at 
24, 48 and 72 h after surgery. Along with our study, the results 
of another study [13] demonstrated that low dose perioperative 
lidocaine (intraoperative lidocaine infusion of 1.5 mg/kg/h 
following a bolus lidocaine of 1.5 mg/kg over postoperative 1 
h) was not effective in controlling either postoperative pain 
perception or secondary hyperalgesia around surgical wounds 
after total hip arthroplasty. The authors suggested that the 
limited postoperative benefit in the hip arthroplasty was likely 
ascribed to the lower amount of lidocaine and its short duration 
of use [13]. Indeed, the use of optimal dosage regimens of i.v. 
lidocaine might have produced different results in this study. 
When considering the effect of dose and duration of lidocaine 
infusion [8,15], a possible criticism for the current study with 
intraoperative low dose of lidocaine may be elicited. However, 
it should be noted that such a low dose and short duration of 
lidocaine infusion with a 1.5 mg/kg of lidocaine bolus 30 min 
before incision followed by 1.5 mg/kg/h lidocaine infusion until 
1 h after skin closure previously demonstrated a significant 
and prolonged improvement in postoperative pain intensity 
and analgesic consumption in a study with major abdominal 
surgery [7]. 
Nevertheless, the analgesic property of lidocaine seems to 
depend on the dose infused. Tremont-Lukats et al. [15] reported 
that the higher dose of lidocaine, 5 mg/kg, was more effective in 
alleviating neuropathic pain compared to lower infusion, which 
was not different from placebo for relief of pain. 
Although systemic lidocaine administration was well tole-
rated without significant complications in previous studies 
[1,4,7-9], a larger dose of lidocaine may induce systemic toxicity. 434 www.ekja.org
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There is a scarcity of studies that systemically assessed the safety 
of i.v. lidocaine. Higher incidence of side effects such as perioral 
numbness and tinnitus was observed in lidocaine treatment 
alone [16]. Close medical observation, which is labor intensive 
and costly, may be required as long as i.v. lidocaine infusion 
is being continued. In addition, as with the current study, by 
stopping lidocaine infusion at the end of surgery, it is possible 
to obtain a lidocaine induced benefit when patients are not 
receiving drug. Further research to determine optimal dose and 
duration of systemic lidocaine infusion providing postoperative 
benefits is necessary in patients undergoing breast surgeries. 
In conclusion, the present study did not show any benefit 
of the intraoperative low dose lidocaine in terms of functional 
recovery of bowel movement, pain intensity, analgesic 
consumption and hospital stay after aesthetic and reconstructive 
breast surgeries.
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